2024-03-28T20:14:42Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/92772023-10-25T10:58:29Zcom_20.500.12105_2060com_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_2061
00925njm 22002777a 4500
dc
Richi, Patricia
author
Martín, María Dolores
author
De Ory, Fernando de
author
Gutiérrez-Larraya, Rosa
author
Casas Flecha, Inmaculada
author
Jiménez-Díaz, Ana María
author
Cava, Fernando
author
Muñoz-Fernandez, Santiago
author
2019
Objective: To evaluate whether immunological response to influenza vaccination is impaired in patients who are receiving secukinumab. Patients and methods: Subjects suffering from psoriatic arthritis or ankylosing spondylitis who were receiving treatment with secukinumab and healthy volunteers were included.All participants received seasonal inactivated trivalent influenza vaccine recommended by the WHO in the 2017-2018 northern hemisphere influenza season, which contained an A/Michigan/45/2015 (H1N1)pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus and a B/Brisbane/60/2008-like virus.Haemagglutination inhibition was used to evaluate basal antibody (Ab) titres against the three influenza vaccine virus strains just before vaccination and at least 4 weeks after the vaccine administration. Response to vaccine was considered as >4-fold increases in Ab titre. Results: Thirty subjects, 17 patients and 13 healthy controls, with a follow-up duration of 33±8 days, were analysed. There were no demographic differences between groups. Patients and controls achieved a median of 4.6-fold and 4.0-fold increases, respectively, for anti H1N1 and almost 4.0 (3.7) for patients and 5.3 for controls for anti-B Ab. Both groups presented a poor response against H3N2, with <1.5-fold increase. Seroconversion rates were similar in both groups. Secukinumab did not influence the response to the influenza vaccine (relative risk: 1.09 (95% CI 0.58 to 2.07) for H1N1, RR: 1.53 (95% CI 0.15 to 15.0) for H3N2 and RR: 0.72 (95% CI 0.32 to 1.83) for B strain). Conclusion: In our study, secukinumab has no effect on the immunogenic response to the influenza vaccine.
RMD Open. 2019 Sep 3;5(2):e001018.
2056-5933
http://hdl.handle.net/20.500.12105/9277
31565246
10.1136/rmdopen-2019-001018
RMD open
Ankylosing Spondylitis
DMARDs (biologic)
Psoriatic arthritis
Vaccination
Secukinumab does not impair the immunogenic response to the influenza vaccine in patients